Online citations, reference lists, and bibliographies.
← Back to Search

Long‐Term Randomized Trial Of Intensive Versus Symptomatic Management In Paget's Disease Of Bone: The PRISM‐EZ Study

A. Tan, K. Goodman, A. Walker, J. Hudson, G. MacLennan, P. Selby, W. Fraser, S. Ralston
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
It has been suggested that normalization of bone turnover may improve clinical outcome in Paget's disease of bone (PDB) by preventing complications such as fractures and the development of osteoarthritis. Here we investigated the long‐term effects of a treatment strategy that aimed to normalize bone turnover in PDB with that of symptomatic treatment. The study group comprised 502 subjects who were enrolled into a 3‐year extension of the Paget's Disease: Randomized Trial of Intensive versus Symptomatic Management (PRISM) study. Intensive bisphosphonate therapy was continued in 270 of these subjects with the aim of normalizing bone turnover using zoledronic acid as the treatment of first choice. Symptomatic treatment continued in 232 subjects in whom bisphosphonates were only given for the treatment of bone pain. The primary outcome was fracture and secondary outcomes were orthopedic procedures, quality of life, and bone pain, adjusted for baseline characteristics. Serum total alkaline phosphatase (ALP) concentrations were significantly lower in the intensive group on entry to the study and the differences between groups increased as the study progressed. There were no clinically important differences in quality of life measures or bone pain between the treatment groups. Intensive treatment was associated with a nonsignificant increase in fracture risk (hazard ratio = 1.90; 95% CI, 0.91 to 3.98; p = 0.087), orthopedic procedures (1.81; 95% CI, 0.71 to 4.61; p = 0.214), and serious adverse events (relative risk 1.28; 95% CI, 0.96 to 1.42). We conclude that long‐term intensive bisphosphonate therapy confers no clinical benefit over symptomatic therapy and is associated with a nonsignificant increase in the risk of fractures, orthopedic events, and serious adverse events. The results of this study suggest that in patients with established PDB, bisphosphonate therapy should focus on control of symptoms rather than suppression of bone turnover. © 2016 American Society for Bone and Mineral Research.
This paper references
10.1136/ard.51.11.1202
Comparison of two approaches to measuring change in health status in rheumatoid arthritis: the Health Assessment Questionnaire (HAQ) and modified HAQ.
S. Ziebland (1992)
10.1002/JBMR.5650111210
Paget's disease of bone and quality of life
D. Gold (1996)
10.1016/S8756-3282(96)00364-X
Alendronate in the treatment of Paget's disease of bone.
S. Khan (1997)
10.1016/S0895-4356(98)00081-X
Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project.
J. Ware (1998)
10.1016/S0002-9343(99)00062-5
A randomized, double-blind comparison of risedronate and etidronate in the treatment of paget’s disease of bone
P. Miller (1999)
A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group.
P. Miller (1999)
The SF-36 ArthritisSpecific Health Index (ASHI): I. Development and crossvalidation of scoring algorithms
Ware JE (1999)
10.1359/jbmr.2001.16.8.1379
A Clinical Approach to Diagnosis and Management of Paget's Disease of Bone
K. Lyles (2001)
10.1359/jbmr.2002.17.3.465
Incidence and Natural History of Paget's Disease of Bone in England and Wales
T. van Staa (2002)
10.1016/S8756-3282(02)00817-7
Guidelines on the management of Paget's disease of bone.
P. Selby (2002)
10.1021/JM020819I
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
L. Widler (2002)
10.1210/JC.2004-0952
Severely suppressed bone turnover: a potential complication of alendronate therapy.
C. Odvina (2005)
10.1056/NEJMOA044241
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
I. Reid (2005)
10.1002/SIM.2053
The use of the propensity score for estimating treatment effects: administrative versus clinical data.
P. Austin (2005)
Clinical practice. Paget's disease of bone.
M. Whyte (2006)
10.1007/s00223-006-0184-2
Clinical Determinants of Quality of Life in Paget’s Disease of Bone
A. Langston (2006)
10.1359/jbmr.061001
Long‐Term Control of Bone Turnover in Paget's Disease With Zoledronic Acid and Risedronate
D. Hosking (2007)
10.1007/s00223-009-9263-5
Bone Turnover in Bone Biopsies of Patients with Low-Energy Cortical Fractures Receiving Bisphosphonates: A Case Series
R. Armamento-Villareal (2009)
10.1359/jbmr.090709
Randomized trial of intensive bisphosphonate treatment versus symptomatic management in paget's disease of bone
Anne L Langston (2010)
10.1002/sim.3762
Estimating the crude probability of death due to cancer and other causes using relative survival models.
P. Lambert (2010)
Randomised trial of intensive bisphosphonate treatment versus symptomatic management in Paget’s disease of bone
AL Langston (2010)
10.2214/AJR.10.6343
Atypical proximal femoral fractures in patients with paget disease receiving bisphosphonate therapy.
A. Kilcoyne (2011)
10.1136/bmj.d40
Strategy for intention to treat analysis in randomised trials with missing outcome data
I. White (2011)
10.1002/jbmr.1998
Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research
E. Shane (2014)
10.1210/jc.2014-2910
Paget's disease of bone: an endocrine society clinical practice guideline.
F. Singer (2014)
Endocrine Society. Paget’s disease of bone: an Endocrine Society Clinical Practice Guideline
FR Singer (2014)
10.1210/jc.2015-1631
Letter to the Editor: The Endocrine Society Clinical Practice Guidelines on Paget's Disease: Many Recommendations Are Not Evidence Based.
S. Ralston (2015)



This paper is referenced by
10.1007/s41970-021-00158-6
Morbus Paget des Knochens – eine aktuelle Übersicht zu Klinik, Diagnostik und Therapie
P. Klemm (2021)
10.1007/s00223-021-00848-x
Long-Term Efficacy of Intensive Zoledronate Therapy and Predictors of Retreatment in Paget's Disease of Bone.
M. Barale (2021)
10.7554/eLife.65715
Epigenetic analysis of Paget’s disease of bone identifies differentially methylated loci that predict disease status
I. Diboun (2021)
10.1101/2021.01.04.425216
Epigenetic analysis of Paget’s disease of bone identifies differentially methylated loci that predict disease status
I. Diboun (2021)
10.1007/s00393-020-00897-x
Morbus Paget des Knochens – eine aktuelle Übersicht zu Klinik, Diagnostik und Therapie
P. Klemm (2020)
10.1002/jbmr.4007
Characteristics of Early Paget's Disease in SQSTM1 Mutation Carriers: Baseline Analysis of the ZiPP Study Cohort
O. Cronin (2020)
10.1093/rheumatology/keaa345
Adult Paget disease of bone: a tale of two guidelines.
S. Tuck (2020)
10.1016/J.JOS.2019.08.023
Long term effects on biochemical bone markers of a single infusion of zoledronic acid in Paget disease of bone.
Celia Rodríguez-Olleros Rodríguez (2020)
10.1016/j.bone.2020.115465
Bisphosphonates in the management of Paget's disease.
S. Ralston (2020)
10.1007/s00393-020-00897-x
[Paget's disease of bone-a current review of clinical aspects, diagnostics and treatment].
P. Klemm (2020)
10.4103/ijem.IJEM_239_20
Paget's Disease of Bone in Tunisia: A Study of 69 Patients
K. Maatallah (2020)
10.1002/jbmr.3873
Clinical Guidelines on Paget's Disease of Bone
S. Ralston (2019)
10.1097/MED.0000000000000503
Paget's disease of bone: updates for clinicians.
Emory Hsu (2019)
10.1007/978-3-030-03694-2_8
Paget’s Disease of Bone
A. Mazhari (2019)
10.1111/jop.12801
Effect of technetium‐99 conjugated with methylene diphosphonate (99Tc‐MDP) on OPG/RANKL/RANK system in vitro
S. Shen (2019)
10.1016/j.jos.2019.08.023
Long term effects on biochemical bone markers of a single infusion of zoledronic acid in Paget disease of bone.
Celia Rodríguez-Olleros Rodríguez (2019)
10.1016/j.jbspin.2019.01.015
Has Paget's bone disease become rare?
L. Michou (2019)
10.1016/J.MONRHU.2018.11.008
La maladie de Paget est-elle devenue une maladie osseuse rare ?
L. Michou (2019)
10.1007/s00223-019-00539-8
Paget’s Disease of Long Bones: Microstructural Analyses of Historical Bone Samples
E. Nebot (2019)
10.1002/jbmr.3657
Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline
S. Ralston (2019)
10.1136/bmjopen-2019-030689
Zoledronate in the prevention of Paget’s (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget’s disease of bone
O. Cronin (2019)
10.1007/s00223-019-00522-3
Paget’s Disease of Bone
L. Gennari (2019)
10.1007/s12020-019-01967-0
Long-term control of Paget’s disease of bone with low-dose, once-weekly, oral bisphosphonate preparations, in a “real world” setting
Y. Liel (2019)
10.1242/dmm.035576
Zoledronic acid prevents pagetic-like lesions and accelerated bone loss in the p62P394L mouse model of Paget's disease
A. Daroszewska (2018)
10.1016/j.metabol.2017.06.010
Paget's disease of bone.
T. Cundy (2018)
10.1080/21678707.2018.1500691
Paget’s disease of bone: an update on epidemiology, pathogenesis and pharmacotherapy
L. Gennari (2018)
10.1007/s12020-018-1806-y
Long-term control of Paget’s disease of bone with low-dose, once-weekly, oral bisphosphonate preparations, in a “real world” setting
Y. Liel (2018)
10.1016/j.beem.2018.05.005
Paget's disease of bone.
N. Appelman-Dijkstra (2018)
10.1016/J.MPORTH.2018.05.009
Paget's disease of bone
A. Fishlock (2018)
10.1016/J.RBR.2017.04.005
Determinantes da qualidade de vida na doença de Paget óssea
G. Castro (2017)
10.1002/jbmr.3156
Treating Paget's Disease—Why and How Much?
T. Cundy (2017)
10.1016/j.rbre.2017.06.002
Determinants of quality of life in Paget's disease of bone.
G. R. Werner de Castro (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar